CN106456576A - 治疗晚期非酒精性脂肪性肝炎的方法 - Google Patents

治疗晚期非酒精性脂肪性肝炎的方法 Download PDF

Info

Publication number
CN106456576A
CN106456576A CN201580022302.1A CN201580022302A CN106456576A CN 106456576 A CN106456576 A CN 106456576A CN 201580022302 A CN201580022302 A CN 201580022302A CN 106456576 A CN106456576 A CN 106456576A
Authority
CN
China
Prior art keywords
compound
formula
liver
patient
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580022302.1A
Other languages
English (en)
Chinese (zh)
Inventor
松田和子
岩城裕
岩城裕一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CN106456576A publication Critical patent/CN106456576A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Alcoholic Beverages (AREA)
  • Steroid Compounds (AREA)
CN201580022302.1A 2014-05-08 2015-05-06 治疗晚期非酒精性脂肪性肝炎的方法 Pending CN106456576A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461990606P 2014-05-08 2014-05-08
US61/990,606 2014-05-08
US201462042072P 2014-08-26 2014-08-26
US62/042,072 2014-08-26
US14/490,618 US9346754B2 (en) 2014-05-08 2014-09-18 Method of treating advanced non-alcoholic steatohepatitis
US14/490,618 2014-09-18
PCT/US2015/029457 WO2015171755A2 (en) 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
CN106456576A true CN106456576A (zh) 2017-02-22

Family

ID=54367221

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580022302.1A Pending CN106456576A (zh) 2014-05-08 2015-05-06 治疗晚期非酒精性脂肪性肝炎的方法

Country Status (10)

Country Link
US (1) US9346754B2 (enExample)
EP (1) EP3139911B1 (enExample)
JP (1) JP6672173B2 (enExample)
KR (1) KR102386018B1 (enExample)
CN (1) CN106456576A (enExample)
BR (1) BR112016025369A2 (enExample)
CA (2) CA2946597C (enExample)
ES (1) ES2964286T3 (enExample)
TW (1) TW201622716A (enExample)
WO (1) WO2015171755A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457306B2 (en) * 2014-10-07 2016-10-04 Life Technologies Corporation Regulated vacuum off-gassing of gas filter for fluid processing system and related methods
EP4346783A1 (en) * 2021-05-28 2024-04-10 MediciNova, Inc. Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158123A1 (en) * 2011-12-08 2013-06-20 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
MXPA06012564A (es) * 2004-04-27 2007-01-31 Medicinova Inc Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
JP2013056834A (ja) * 2011-09-07 2013-03-28 Okayama Univ 線維化疾患治療剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158123A1 (en) * 2011-12-08 2013-06-20 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNA WIECKOWSKA ET AL: "Nonalcoholic fatty liver disease in the pediatric population:a review", 《CURR OPIN PEDIATR》 *

Also Published As

Publication number Publication date
BR112016025369A2 (pt) 2017-08-15
KR102386018B1 (ko) 2022-04-14
CA3205812A1 (en) 2015-11-12
KR20170003581A (ko) 2017-01-09
CA2946597C (en) 2023-09-12
WO2015171755A2 (en) 2015-11-12
ES2964286T3 (es) 2024-04-05
JP2017518967A (ja) 2017-07-13
EP3139911A4 (en) 2017-12-20
EP3139911A2 (en) 2017-03-15
EP3139911B1 (en) 2023-10-25
US9346754B2 (en) 2016-05-24
CA2946597A1 (en) 2015-11-12
US20150322004A1 (en) 2015-11-12
JP6672173B2 (ja) 2020-03-25
TW201622716A (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
JP2019218379A (ja) 肝障害の治療方法
JP6608404B2 (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
CA2817757A1 (en) Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
JP6672173B2 (ja) 進行した非アルコール性脂肪性肝炎の治療方法
WO2017155053A1 (ja) 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤
CN106232108B (zh) 治疗特发性肺纤维化的制药用途
JP6469727B2 (ja) 線維症の抑制又は治療方法
TW202237092A (zh) 作為冠狀病毒抗病毒劑之泰若美沛可(terameprocol)及降二氫癒創木酸(nordihydroguaiaretic acid) (ndga)衍生物
CN119700764B (zh) 恩波吡维铵在制备抗基孔肯亚病毒感染药物中的应用
US20150320705A1 (en) Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids
CN111973597A (zh) Abemaciclib在制备治疗NAFLD的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222